The failure of the MERU trial is the latest in a string of disappointments for Rova-T, which was the basis for the Stemcentrix deal. Earlier this year, the company culled 178 employees from Bay Area-based Stemcentrix as a response to those failures. Prior to the MERU trial, in December 2018, AbbVie halted a Phase III study of Rovalpituzumab Tesirine (Rova-T) as a second-line treatment for advanced small-cell lung cancer. That trial was halted after an IDMC called for the stoppage due to shorter overall survival in the Rova-T arm. AbbVie also announced last year that it would not seek accelerated approval for Rova-T in third-line relapsed/refractory (R/R) small cell lung cancer (SCLC) following disappointing results in the Phase II TRINITY trial.
Four independent studies published in the Journal of Thoracic Oncology demonstrate that rovalpituzumab tesirine (Rova-T), a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), is not effective against small cell lung cancer (SCLC). An accompanying editorial by Uprety et al explores recent clinical trials of rovalpituzumab and suggests possible reasons why the drug has not been effective.
vkt lkbrova Mp3
Download 🔥 https://tlniurl.com/2y7Pzf 🔥
006ab0faaa
download the mac cisco anyconnect vpn client
easy steps to chinese 4 pdf download
download llama llama spit spit
anubhav mohanty mp3 song download